Abstract: Introduction: Prazosin is an antihypertensive medication which
can be used to help with
post-traumatic stress disorder (PTSD) symptoms. Little data is currently
available on its safety in pregnancy.Objective: To assess the fetal and pregnancy safety associated
with Prazosin exposures in early Pregnancy.Methods: Subjects were 11 patients who took Prazosin during
pregnancy and were counselled at the FRAME clinic in London Health
Sciences Centre (Ontario, Canada) between January 1, 2000 to December
31, 2021. Data on their other exposures and pregnancy outcomes were
collected from medical records and through telephone questionnaires.Results: It was found that 6 /11 (54.5%) subjects did not
report any adverse outcomes and were uneventful pregnancies. There were
2 miscarriages. Birthweights were within the normal range for the
remaining 9 pregnancies. Adverse events reported were consistent with
background population expectation, including: 1 postpartum hemorrhage, 1
case of preeclampsia, 1 preterm birth, 2 NICU admissions, and 2
caesarean sections.Discussion / Conclusion: For these 11 subjects, pregnancy
outcomes after exposure to Prazosin were consistent with typical
outcomes from unexposed pregnancies. More data are needed to conclude
that Prazosin is safe for use in pregnant subjects. However, the lack of
adverse effects above baseline is reassuring to future patients who may
be unintentionally exposed to Prazosin while pregnant. Therefore, this
study contributes valuable data toward monitoring safety of Prazosin in
Pregnancy.